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not identical, means.” In the equally rapidly chang-
ing field of metastatic breast cancer, our Practice 
Guideline series reviews the role of h e r 2-targeted 
therapies in women with h e r 2-overexpressing 
metastatic breast cancer.
Elsewhere in the issue, the role of r n a  in promoting 
and regulating cancer is comprehensively reviewed by 
Drs. Thomas Duchaine and Frank Slack. This topic 
area is potentially of huge importance not only for 
understanding this microenvironment, but also for the 
development of additional targeted cancer therapies.
Strong representation from Canadian radiation 
centres in Current Oncology continues with an over-
view of the results of bladder-conserving cancer 
therapies. Dr. Luis Souhami and colleagues closely 
scrutinize a strategy, largely developed and promoted 
within Canada, that takes a trimodal approach to the 
management of muscle-invasive disease. Although 
most bladder cancers are superficial at presentation, 
disease at this site is the ninth most frequent cancer 
seen worldwide.
The journal continues to expand its hybrid concept 
for some manuscripts of a more specialized nature. 
Expanded abstracts of these papers appear in the print 
issue with links to the full versions published online. 
This presentation achieves a secondary benefit of 
more speedy publication. Printing Current Oncology 
is a costly venture, and we believe that the hybrid 
format is in the long-term best interest not only of the 
journal, but also of our readers and contributors.
We trust that readers will find all of this issue’s 
articles enlightening and thought-provoking.
In Canada, many patients undergoing cancer treat-
ment are faced with exceptional costs—because of 
travel and related expenses, for instance—not always 
experienced in other jurisdictions. In a review titled 
“Perceptions of health care providers concerning 
patient and health care provider strategies to limit 
out-of-pocket costs for cancer care,” Dr. Maria Mat-
thews and colleagues look at these “soft” costs from 
the perspective of patients in Canada’s most easterly 
province. The article sets out some of the strategies 
that cancer patients and their caregivers are both 
forced to use to limit the burden, which moreover 
falls somewhat disproportionately on rural as compared 
with urban patients.
The guest editorial in this issue of Current Oncology 
finds Dr. Louis Touyz questioning the rationale of 
immunizing only girls against the human papilloma 
virus; and in a not-dissimilar vein, Drs. Joshua Uronis 
and Christian Jobin take note of the 100 trillion bacterial 
and like particles in the “average” colon and review 
the evidence for colon-based microorganism-mediated 
signals for tumour suppression and promotion.
In the rapidly changing field of advanced non-
small-cell lung cancer, “responsive clinicians face 
difficult tradeoffs as they try to balance the pros 
and cons of early adoption [of new therapies] with 
excessive conservatism.” Dr. Mark Vincent invites 
us to peruse a “personal view of how to navigate 
these waters,” which “although ... written espe-
cially for patients who like to be the captain of their 
own ship, [holds] good reason to believe that all 
patients will eventually be managed by similar, if 